Raynaud phenomenon: from GWAS to drug repurposing

Ariane L Herrick; Gisela Orozco

doi:10.1038/s41584-024-01076-x

Raynaud phenomenon: from GWAS to drug repurposing

Ariane L Herrick, Gisela Orozco

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Commentary/debate

Abstract

The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α _2A-adrenoceptors, and suggests opportunities for drug repurposing.

Original language	English
Pages (from-to)	139-140
Number of pages	2
Journal	Nature Reviews. Rheumatology
Volume	20
Issue number	3
Early online date	16 Jan 2024
DOIs	https://doi.org/10.1038/s41584-024-01076-x
Publication status	Published - 1 Mar 2024

Keywords

Drug Repositioning
Genome-Wide Association Study
Humans
Raynaud Disease/drug therapy

Access to Document

10.1038/s41584-024-01076-x

Cite this

@article{ddd950aab6c841419016cc7cac85d414,

title = "Raynaud phenomenon: from GWAS to drug repurposing",

abstract = "The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α 2A-adrenoceptors, and suggests opportunities for drug repurposing.",

keywords = "Drug Repositioning, Genome-Wide Association Study, Humans, Raynaud Disease/drug therapy",

author = "Herrick, {Ariane L} and Gisela Orozco",

year = "2024",

month = mar,

day = "1",

doi = "10.1038/s41584-024-01076-x",

language = "English",

volume = "20",

pages = "139--140",

journal = "Nature Reviews. Rheumatology",

issn = "1759-4790",

publisher = "Nature Research",

number = "3",

}

TY - JOUR

T1 - Raynaud phenomenon

T2 - from GWAS to drug repurposing

AU - Herrick, Ariane L

AU - Orozco, Gisela

PY - 2024/3/1

Y1 - 2024/3/1

N2 - The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α 2A-adrenoceptors, and suggests opportunities for drug repurposing.

AB - The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α 2A-adrenoceptors, and suggests opportunities for drug repurposing.

KW - Drug Repositioning

KW - Genome-Wide Association Study

KW - Humans

KW - Raynaud Disease/drug therapy

UR - http://www.scopus.com/inward/record.url?scp=85182478258&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/2ede9afb-00d7-30de-a614-f59ec3bd4d29/

U2 - 10.1038/s41584-024-01076-x

DO - 10.1038/s41584-024-01076-x

M3 - Commentary/debate

C2 - 38228855

SN - 1759-4790

VL - 20

SP - 139

EP - 140

JO - Nature Reviews. Rheumatology

JF - Nature Reviews. Rheumatology

IS - 3

ER -

Raynaud phenomenon: from GWAS to drug repurposing

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this